Merck KGaA’s (MRK) Neutral Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of Merck KGaA (FRA:MRK) in a research note released on Wednesday.

Other analysts have also issued research reports about the stock. Warburg Research set a €115.00 ($136.90) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Tuesday, September 26th. UBS Group initiated coverage on shares of Merck KGaA in a research report on Tuesday, September 26th. They set a buy rating and a €120.00 ($142.86) price target on the stock. Citigroup set a €123.00 ($146.43) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Monday, September 25th. Berenberg Bank set a €116.00 ($138.10) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Monday, October 2nd. Finally, Oddo Bhf set a €125.00 ($148.81) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Friday, September 29th. Twelve equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Merck KGaA presently has a consensus rating of Hold and an average price target of €107.57 ($128.06).

Shares of Merck KGaA (FRA:MRK) opened at €89.66 ($106.74) on Wednesday. The company has a market cap of $11,650.00 and a price-to-earnings ratio of 21.00. Merck KGaA has a 52-week low of €87.33 ($103.96) and a 52-week high of €115.00 ($136.90).

COPYRIGHT VIOLATION NOTICE: This report was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://stocknewstimes.com/2018/01/21/merck-kgaas-mrk-neutral-rating-reiterated-at-jpmorgan-chase-co.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply